Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Total Liabilities: 2021-2025

Historic Total Liabilities for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $30.7 million.

  • Amylyx Pharmaceuticals' Total Liabilities fell 43.60% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 43.60%. This contributed to the annual value of $28.9 million for FY2024, which is 65.64% down from last year.
  • According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' Total Liabilities is $30.7 million, which was up 15.06% from $26.7 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Total Liabilities registered a high of $93.0 million during Q1 2024, and its lowest value of $17.4 million during Q4 2021.
  • For the 3-year period, Amylyx Pharmaceuticals' Total Liabilities averaged around $52.5 million, with its median value being $54.5 million (2024).
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Total Liabilities soared by 191.70% in 2022, and later tumbled by 80.37% in 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Total Liabilities (Quarterly) stood at $17.4 million in 2021, then skyrocketed by 191.70% to $50.8 million in 2022, then spiked by 65.25% to $84.0 million in 2023, then slumped by 65.64% to $28.9 million in 2024, then slumped by 43.60% to $30.7 million in 2025.
  • Its last three reported values are $30.7 million in Q3 2025, $26.7 million for Q2 2025, and $18.3 million during Q1 2025.